Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor

8 Feb 2024

Abstract excerpt

Abstract Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection in infants, older adults and the immunocompromised. Effective directly acting antivirals are not yet available for clinical use. To address this, we screen the ReFRAME drug-repurposing library consisting of 12,000 small molecules against RSV. We identify 21 primary candidates including RSV F and N protein...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Respiratory viral infections research
Share to Viral Infections and Outbreaks Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38332002
DOI: 10.1038/s41467-024-45241-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitorPMID 38332002Read ↗

Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC.Semantic proximity Read ↗

Structure-guided design of small-molecule therapeutics against RSV diseaseSemantic proximity Read ↗

Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance ProfilesSemantic proximity Read ↗

Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA VirusesSemantic proximity Read ↗

Discovery of a non-nucleoside inhibitor that binds to a novel site in the palm domain of the respiratory syncytial virus RNA-dependent RNA polymeraseSemantic proximity Read ↗

Characterization of a Respiratory Syncytial Virus L Protein InhibitorSemantic proximity Read ↗

Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery.Semantic proximity Read ↗

Mechanism of Action for Respiratory Syncytial Virus Inhibitor RSV604Semantic proximity Read ↗

Characterization of novel respiratory syncytial virus inhibitors identified by high throughput screen.Semantic proximity Read ↗

Antiviral drug synergy and mutational signatures in different epithelial cell models of RSV and hPIV infectionSemantic proximity Read ↗

Structural Mapping of Surveillance Data Reveals Conservation of NNI Binding Site in RSV L Protein.Semantic proximity Read ↗

EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.